首页> 外文期刊>Recent Patents on Inflammation & Allergy Drug Discovery >Potential of Lung Surfactant Proteins, SP-A and SP-D, and Mannan Binding Lectin for Therapy and Genetic Predisposition to Allergic and Invasive Aspergillosis
【24h】

Potential of Lung Surfactant Proteins, SP-A and SP-D, and Mannan Binding Lectin for Therapy and Genetic Predisposition to Allergic and Invasive Aspergillosis

机译:肺表面活性蛋白,SP-A和SP-D以及甘露聚糖结合凝集素对过敏性和侵袭性曲霉病的治疗和遗传易感性

获取原文
获取原文并翻译 | 示例
           

摘要

A significant proportion of bronchial asthma patients have underlying pulmonary fungal infections that contribute to persistent inflammation and allergic reactions. Aspergillus fumigatus is a ubiquitous opportunistic fungal pathogen causing a spectrum of allergic and infectious diseases. Currently, oral corticosteroids form the first line of treatment for allergic aspergillosis and use of antifungals such as itraconazole has been indicated in non-responders. In view of the protective role of innate immunity in host defense against Aspergillus fumigatus, we aimed to identify the relevant innate immune proteins In a series of studies, we identified and established the therapeutic potential of pulmonary collectins SP-A and SP-D and serum collectin MBL in murine models of allergic and invasive aspergillosis. Use of SP-D for diagnosis and therapy of lung disorders and MBL for therapy of various infections including invasive aspergillosis has been patented. Genetic polymorphisms in these genes may result in partial or total loss of function and may increase the host's susceptibility to aspergillosis. Candidate gene association studies showed SNPs in SP-A2 and MBL significantly associate with patients of allergic bronchopulmonary aspergillosis and bronchial asthma with rhinitis. The patients carrying either one or both of GCT and AGG alleles of SP-A2 and patients with A allele at position 1011 of MBL had markedly higher eosinophilia, total IgE antibodies and lower FEV1 (the clinical markers of ABPA). These SNPs may be useful for predicting susceptibility to allergic aspergillosis and bronchial asthma with allergic rhinitis and have been patented. Elucidation of the immunoregulatory role of SP-A, SP-D and MBL in mechanisms of allergy and inflammation suggests that they may also be potentially useful for predisposition diagnosis and therapy of non-fungal bronchial asthma.
机译:很大比例的支气管哮喘患者具有潜在的肺部真菌感染,导致持续的炎症和过敏反应。烟曲霉是一种普遍存在的机会性真菌病原体,可引起一系列过敏性和传染性疾病。目前,口服皮质类固醇是过敏性曲霉病的第一线治疗方法,无应答者已表明使用抗真菌药如伊曲康唑。鉴于先天免疫在宿主对抗烟曲霉中的保护作用,我们旨在鉴定相关的先天免疫蛋白。在一系列研究中,我们确定并确定了肺集蛋白SP-A和SP-D和血清的治疗潜力变应性和侵袭性曲霉菌病小鼠模型中的collectin MBL。 SP-D用于诊断和治疗肺部疾病,MBL用于治疗包括侵袭性曲霉病在内的各种感染已获得专利。这些基因的遗传多态性可能导致部分或全部功能丧失,并可能增加宿主对曲霉病的易感性。候选基因关联研究表明,SP-A2和MBL中的SNP与过敏性支气管肺曲霉病和支气管哮喘伴鼻炎患者显着相关。携带SP-A2的GCT和AGG等位基因之一或两者的患者,以及在MBL 1011位置具有A等位基因的患者,嗜酸性粒细胞增多,总IgE抗体和FEV1(ABPA的临床标志物)明显降低。这些SNP可用于预测对过敏性鼻炎和过敏性鼻炎的支气管哮喘的敏感性,并已获得专利。 SP-A,SP-D和MBL在变态反应和炎症机制中的免疫调节作用的阐明表明,它们也可能对非真菌性支气管哮喘的易感性诊断和治疗有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号